LivaNova PLC (NASDAQ:LIVN) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 39.1% during the fourth quarter, Holdings Channel reports. The fund owned 12,971 shares of the company’s stock after selling 8,331 shares during the quarter. Headlands Technologies LLC’s holdings in LivaNova were worth $601,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Central Pacific Bank Trust Division boosted its holdings in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the last quarter. Vestcor Inc acquired a new stake in LivaNova in the 4th quarter worth about $204,000. Captrust Financial Advisors purchased a new stake in LivaNova in the 3rd quarter valued at about $217,000. Inceptionr LLC purchased a new position in shares of LivaNova during the 4th quarter worth about $217,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of LivaNova during the 3rd quarter worth about $219,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LIVN has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Barclays cut their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th. Finally, Stifel Nicolaus decreased their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Price Performance

LIVN stock opened at $39.50 on Thursday. The stock has a 50-day simple moving average of $43.94 and a 200-day simple moving average of $48.29. The firm has a market cap of $2.15 billion, a P/E ratio of 94.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.